Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Uterine Cervical Neoplasms 1Stomach Neoplasms 1Esophageal Neoplasms 1Colorectal Neoplasms 1Breast Neoplasms 1

Interventions

Oxaliplatin 42Fluorouracil 27Capecitabine 24pembrolizumab 21S 1 (combination) 19Paclitaxel 19Leucovorin 16Nivolumab 13Docetaxel 13sintilimab 12Drug Therapy 12Trastuzumab 11tislelizumab 10Cisplatin 10Irinotecan 9Bevacizumab 8trastuzumab deruxtecan 7spartalizumab 7XELOX 7Surgical Procedures, Operative 7Radiotherapy 7Hyperthermic Intraperitoneal Chemotherapy 7Biopsy 7fludarabine 6disitamab vedotin 6Cyclophosphamide 6lenvatinib 5apatinib 5Specimen Handling 5Ramucirumab 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Stomach Neoplasms × Risk Assessment × Clear all
NCT06306755 2025-01-24

ERSS-EGC

Peking University Cancer Hospital & Institute

Phase NA Recruiting
21,000 enrolled
Gastrointestinal

Esophageal Neoplasms, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡